InflaRx N.V. (IFRX) regained compliance with Nasdaq’s minimum bid‑price requirement on April 24, 2026, after its ordinary shares traded at $1.00 or higher for ten consecutive business days, from April 13 to April 24. Nasdaq’s Listing Qualifications Department confirmed the achievement and closed the matter.
The Nasdaq Listing Rule 5450(a)(1) mandates that a company’s bid price remain at or above $1.00 for ten consecutive business days to maintain listing status. By meeting this threshold, InflaRx eliminates the immediate risk of delisting and preserves its ability to raise capital and maintain investor confidence.
InflaRx’s compliance history shows a pattern of volatility. The company received a deficiency notice on March 11, 2026, for 30 consecutive business days below the $1.00 minimum, with a compliance deadline of September 7, 2026. It had previously regained compliance on September 12, 2025, after a period of non‑compliance that began in late August 2025.
Financially, InflaRx is well positioned to support its clinical development. As of March 31, 2025, the company held €65.7 million ($30.0 million from a February 2025 offering plus cash and marketable securities), providing a runway into 2027 and backing its lead programs izicopan and vilobelimab.
Regaining compliance removes the immediate delisting risk, maintains investor confidence, and ensures continued access to capital markets—critical for funding the company’s pipeline and sustaining its growth trajectory.
The event underscores InflaRx’s ability to navigate regulatory requirements and maintain its public listing, reinforcing its position as it advances its therapeutic programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.